key: cord-0773998-1k4chpz5 authors: Thalji, Nabil K.; Patel, Prakash A.; Elliott, Matthew; Augoustides, John G. title: Hematological Consequences of the Coronavirus Crisis – focus on relevant clues and complications for the perioperative cardiothoracic and vascular community date: 2020-05-27 journal: J Cardiothorac Vasc Anesth DOI: 10.1053/j.jvca.2020.05.032 sha: 153c30212eefd618c5be1cf37fbb64d67ea8605f doc_id: 773998 cord_uid: 1k4chpz5 nan The coronavirus pandemic is a global crisis and has led to a surge in hospital-based care for severe coronavirus disease-2019 (COVID- 19) . [1] [2] [3] [4] [5] The unique considerations for severe COVID- 19 have resulted in agile adaptation in the clinical arena, including graduate medical education, echocardiography, perioperative care, critical care and extracorporeal membrane oxygenation. [6] [7] [8] [9] [10] [11] [12] The purpose of this freestanding editorial is to highlight the hematological consequences of the COVID-19 pandemic as they provide clues and challenges for the delivery of high-quality patient care. These features can inform the design of best practices to navigate this crisis creatively. The provided references can also assist thought leaders in their management of the pandemic at their respective institutions. The white blood cell response to coronavirus infection is characterized by lymphopenia. [13] [14] The development of lymphopenia is nearly universal in clinically significant COVID-19 with an observed incidence range of (80-100)%. [13] [14] [15] The degree of the lymphopenic response may significantly correlates with the severity of clinical infection. [14] [15] The extent of the lymphopenia has significantly predicted the risks of admission to the intensive care unit, development of adult respiratory distress syndrome, and mortality. [13] [14] [15] [16] [17] [18] There appear to be multiple mechanisms for this lymphopenic phenotype in COVID-19. The first mechanism is that coronavirus can infect and directly destroy lymphocytes since they express the viral-binding protein on their surface membrane, namely angiotensin-converting enzyme 2. [19] [20] A second mechanism for lymphopenia may be increased lymphocytic apoptosis due to the cytokine storm that may accompany infection with coronavirus. 7; 21 This cytokine storm may also result in atrophy of lymphoid reserves, including the spleen and impair 4 lymphocyte levels. 22 A third mechanism for lymphopenia may be decreased proliferation from significant acidosis associated with severe COVID-19. 3-5; 23 Beyond lymphopenia, recent evidence from multiple clinical trials has suggested that thrombocytopenia is not only common but is very often associated with severe COVID-19. 24 Although the severity of the thrombocytopenia may at times correlate with the clinical severity of coronavirus infection, there may also be a platelet spike in the setting of a pronounced cytokine storm. 24 This relative platelet excess may result in an elevated platelet/lymphocyte ratio that appears to be an independent predictor for prolonged hospitalization and adverse clinical outcomes in COVID-19. [24] [25] [26] These platelet abnormalities may also have role in the disordered coagulation that may accompany COVID-19 and that is explored further in the following section. Recent reports have demonstrated that COVID-19 may be complicated by thrombotic events in a variety of vascular beds, accompanied by markedly elevated D-dimer levels. [26] [27] [28] [29] [30] This hypercoagulability may precipitate both arterial and venous thrombosis. Ischemic stroke, myocardial infarction, deep venous thrombosis, pulmonary embolism, and line-associated thrombosis have been described. A retrospective cohort study of 388 patients in Milan reported a cumulative rate of thromboembolic events of 21% in all hospitalized patients and 27.6% in patients receiving critical care. 29 A Dutch study reported an incidence of thromboembolic events of 31% in ICU patients. 39 However, the concerns over thrombosis in COVID-19 are not limited to overt thromboembolic events. 26 The pattern of preserved pulmonary compliance and profound hypoxemia in severe COVID-19 has led to speculation that pulmonary microvascular thrombosis may be a significant contributor to respiratory failure in this setting. [31] [32] If pulmonary thrombotic burden is critical, it could lead to ventilation-perfusion 5 mismatch and significant hypoxemia. Indeed, since thrombotic risk increases with age, thrombotic events could partially explain the age-associated mortality of COVID-19. 33 Given these risks of thrombosis, therapeutic anticoagulation in COVID-19 has been suggested as part of clinical management. [32] [33] [34] The laboratory findings in COVID-19 include elevated D-dimers, suggesting high fibrinogen turnover. [26] [27] [28] Furthermore, D-dimer levels predict not only clinical severity but also mortality. 34 These levels may be as high as 10 times normal in severe COVID-19. 32-34 Although these D-dimer levels can be remarkably high, further features of disseminated intravascular coagulation may not be present. [35] [36] [37] The fibrinogen levels are elevated, thrombocytopenia is not always present, and the prothrombin as well as the activated partial thromboplastin times are either normal or minimally elevated. 38 Although antiphospholipid antibodies have been observed in this setting, this is not a uniform finding. [38] [39] Furthermore, while disseminated intravascular coagulation typically presents as a mix of thrombosis and bleeding, the coagulation disturbance in COVID-19 appears to be primarily thrombotic. [26] [27] [28] [29] Because of these features, further testing with thromboelastography has been explored to further characterize the prothrombotic effects of COVID -19. 38 The reported coagulation profile in this setting includes shortened clot times, increased maximum amplitude, and delayed clot lysis with a contact pathway initiator. 38 In addition to elevated fibrinogen and D-dimer levels, factor VIII and von Willebrand factor levels were also elevated, while antithrombin levels were mildly decreased to about 75% of normal. 38 These findings provide further evidence that the microvascular thrombosis in severely ill patients with COVID-19 is often not consistent with disseminated intravascular coagulation that may accompany severe sepsis. 41 The clinical and laboratory evidence described above suggest 6 that the microvascular thrombosis in COVID-19 patients has many distinct difference that may also offer some clues about the mechanism of the disease process. The first observation is that it does not exhaust fibrinogen stores, which suggests that the normal hemostatic regulatory mechanisms can limit 'runaway' coagulation activation. 38 The thrombosis that occurs in COVID-19 is probably the result of multiple foci of triggered coagulation. The second observation is that thrombocytopenia may not always be present, suggesting alternative drivers for this thrombotic disorder, including viral endothelial damage and marked complement activation. 20; 26; 31-32; 36 Mechanisms beyond complement activation must also be considered for the thrombotic disorder in COVID-19. The elevated fibrinogen and factor VIII levels could also lead to thrombosis. 38 However, these proteins are both acute phase reactants and therefore their elevated levels alone are unlikely to explain the differences in thrombosis between COVID-19 and other severe inflammatory states. 42 The prothrombotic features of COVID-19 may also be triggered by damage-associated molecular patterns such as neutrophil extracellular traps. 43 These molecules contribute to disordered coagulation in inflammatory states through monocyte activation to link inflammation and thrombosis. 41; 43-44 Neutrophil extracellular traps have been observed in COVID-19 plasma and may offer not only an explanation for the thrombotic features of COVID-19 but also a therapeutic targer. [45] [46] [47] [48] As the pandemic progresses, patients with COVID-19 may require cardiac surgery. [1] [2] Given the importance of hemostasis in cardiac surgery and the disordered coagulation system in COVID-19, there may be important implications for the perioperative management of cardiac surgical patients. An important example of this is perioperative anticoagulation monitoring. Since factor VIII levels may at times be markedly elevated in COVID-19, this may lead to artificially lower clotting times in contact-dependent assays such as the activated clotting time 7 and the partial thromboplastin time. 49 This resulting over-anticoagulation may precipitate bleeding complications. Adequate anticoagulation must however, be maintained both for cardiopulmonary bypass and extracorporeal membrane oxygenation, given the risks of hypercoagulability in this setting. 2-3; 50-51 Disordered coagulation in COVID-19 is a key consideration that contributes to large and small vessel thrombosis. These thrombotic complications contribute to mortality and have unique features that require further investigation to advance clinical management. The COVID-19 pandemic has precipitated an acute shortage of blood products mostly from reduced blood donation due to social distancing. [51] [52] [53] This has prompted a series of public awareness programs to restore blood donation in a safe and appropriately adapted fashion to maintain a national blood supply. [51] [52] [53] Further attention to managing demand has also been advocated as a important strategy to navigate this crisis. 53 The measures that could ease demand include higher transfusion thresholds, and multimodal guideline-driven perioperative blood management. [54] [55] [56] These measures have been covered in detail elsewhere in the journal for both adult and pediatric cardiothoracic and vascular practice. [54] [55] [56] The priority through the pandemic is balance supply with demand in this space. The hematological response to COVID-19 significantly guides diagnosis and management in this challenging disease. The prothrombotic vascular milieu is likely multifactorial but should be considered in tailored patient management. A sustained focus on infection control and blood management remains essential. Intensive care management of coronavirus disease (COVID-19): challenges and recommendations Chinese Society of Anesthesiology expert consensus on anesthetic management of cardiac surgical patients with suspected or confirmed coronavirus disease Extracorporeal membrane oxygenation -crucial considerations during the coronavirus crisis J Cardiothorac Vasc Anesth Clinical management of severe acute respiratory infection when novel coronavirus (2019-nCoV) infection is suspected -interim guidance. (full details available at this link -last accessed May Critical care during the coronavirus crisis -challenges and considerations for the cardiothoracic and vascular anesthesia community Anesthetic management of patients with suspected or confirmed 2019 novel coronavirus infection during emergency procedures Cardiovascular consequences and considerations of coronavirus infectionperspectives for the cardiothoracic anesthesiologist and intensivist during the coronavirus crisis J Cardiothorac Vasc Anesth Perioperative echocardiography -key considerations during the coronavirus pandemic Perioperative echocardiography during the coronavirus crisisconsiderations in pediatrics and congenital heart disease J Cardiothorac Vasc Anesth Anesthesia management and perioperative infection control in patients with the novel coronavirus Response and operating room preparation for the COVID-19 outbreak: a perspective from the National Heart Centre Singapore Fellowship training in adult cardiothoracic anesthesiology -navigating the new educational landscape due to the coronavirus crisis Clinical characteristics of coronavirus disease 2019 in China Clinical features of patients infected with 2019 novel coronavirus in Wuhan Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China Hematologic parameters in patients with COVID-19 infection Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa The renin-angiotensin-aldosterone system in coronavirus infectioncurrent considerations during the pandemic J Cardiothorac Vasc Anesth IL-19 induces production of IL-6 and TNF -alpha and results in cell apoptosis through TNF-alpha Simulation of the clinical and pathological manifestations of coronavirus disease 2019 (COVID -19) in golden Syrian hamster model: implications for disease pathogenesis and transmissibility Inhibitory effect of tumor cell-derived lactic acid on human T cells Thrombocytopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: a meta-analysis Platelet-to-lymphocyte ratio is associated with prognosis in patients with coronavirus disease -19 Hematological findings and complications of COVID-19 Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan ISTH interim guidance on recognition and management of coagulopathy in COVID-19 Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: an updated analysis Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: a report of five cases COVID-19: Progression of disease and intravascular coagulationpresent status and future perspectives Ageing and thrombosis Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia Will complement inhibition be the new target in treating COVID-19 related systemic thrombosis? Circulation 2020 {Epub ahead of print COVID-19 and haemostasis: a position paper from the Italian Society of Thrombosis and Haemostasis Hypercoagulability of COVID-19 patients in intensive care unit: a report of thromboelastography findings and other parameters of hemostasis Coagulopathy of COVID-19 and antiphospholipid antibodies Coagulopathy and antiphospholipid antibodies in patients with Covid-19 Coagulopathy of acute sepsis Elevated factor VIII levels and the risk of thrombosis Sepsis-induced coagulopathy and disseminated intravascular coagulation Neutrophil extracellular traps in immunity and disease Neutrophil extracellular traps in COVID-19. JCI Insight The role of neutrophil extracellular traps in COVID-19: only an hypothesis or a potential new field of research Targeting potential drivers of COVID-19: neutrophil extracellular traps Harnessing innate immunity to eliminate SARS-CoV-2 and ameliorate COVID-19 disease Effects of factor VIII levels on the APTT and anti-Xa activity under a therapeutic dose of heparin Acute thrombosis of an aortic prosthetic graft in a patient with severe COVID-19-related pneumonia High risk of thrombosis in patients with severe SARS-CoV-2 infection; a multicenter, prospective cohort study Prepare to adapt: blood supply and transfusion support during the first 2 weeks of the 2019 novel coronavirus (COVID-19) pandemic affecting Washington State Balancing supply and demand for blood during the COVID-19 pandemic Patient blood management for neonates and children undergoing cardiac surgery EACTS/EACTA guidelines on patient blood management for adult cardiac surgery Anemia and patient blood management in cardiac surgery: literature review and current evidence